|
|
|
Alok Aggarwal
Co-Founder and Chairman
Evalueserve
Dr. Alok Aggarwal is the Co-founder and Chairman of Evalueserve. He started the company in December 2000, which has now grown to 2,300 people located
in global delivery centres in India, China, Chile and Romania.
In July 1997, Dr. Aggarwal founded the IBM India Research Laboratory at the Indian Institute of Technology (IIT), Delhi. He started from ‘ground zero’ and built
it into a 60-member team by July 2000, by which time he was the Director of Emerging Business Opportunities for IBM Research Division worldwide. In this
capacity, his responsibilities included converting business innovations into business models and introducing them to the market to create profitable
organizations.
Dr. Aggarwal has established himself as the first-generation entrepreneur in a new industry segment within the Research and Analytics domain, which has
emerged as a USD 12 billion industry with the potential to create 255,000 jobs by 2010 for professionals worldwide.
He is a role model for emerging leaders in the field of R&D and innovation. His achievements and work inspire young professionals to contribute to society and
the economy while also nurturing and developing a career path for them.
At Evalueserve, a knowledge-driven organization, Dr. Aggarwal has truly embedded a culture of innovation and ‘out-of-the-box’ thinking.
___________________________________________________________________________________________________________
|
|
|
|
Debbie Allison, M.S.
Senior Director, Global Corporate Licensing
Merck
Debbie Allison is Senior Director of Global Competitive Intelligence at Merck & Co., Inc. She has been with Merck for 30 years and worked in the competitive
intelligence arena for over 9 years. Debbie leads the effort to ensure that Merck's competitive and strategic information systems and processes remain premier
within the industry. Her responsibilities also include providing competitive intelligence to the oncology franchise.
Debbie earned a Bachelor's degree in chemistry from The College of William and Mary and a Master's degree in medicinal chemistry from The Ohio State
University. Debbie joined Merck in 1979 as a Medicinal Chemist, supporting programs focused on discovery and development of anti-inflammatory agents.
Debbie left the labs in the mid 1980s to lead a cross-divisional, international effort to put real-time chemical structure and reaction information at the chemist's
desktop through a complete transformation of computer-based information systems. The subsequent move to the Competitive Information group was a perfect
fit for Debbie's talent in assimilating data and computer systems with user's need for strategic insight.
"My passion is to utilize scientific and business information to help establish strategic direction for Merck."
_____________________________________________________________________________________________________________________________
|
| |
|
Biren Amin
Vice President
FTN Equity Capital
Biren Amin covers the biotechnology sector for institutional investors. From 2005 to early 2009, Biren was a biotechnology and healthcare analyst for Stanford
Group. Prior to Stanford, he supported coverage of the large-cap pharmaceutical sector at Prudential Equity Group. Biren also worked at Aventis
Pharmaceuticals (now Sanofi-Aventis) primarily in their competitive intelligence group for 4 years. Biren currently holds a registered pharmacist license in the
State of Pennsylvania. Biren received his M.B.A. from NYU’s Stern School of Business, his M.S. and B.S. in Pharmacy from Long Island University and
University of Sciences in Philadelphia, respectively.
_____________________________________________________________________________________________________________________________
|
| |
|
Peter Aprahamian
Director, Global Competitive Intelligence
Merck
In this role, Peter will be responsible for effectively supporting the protection of Merck's Intellectual Property and commercial rights through surveillance and
appropriate defense strategies.
During his years with Merck, Peter has held several positions within both Finance and Marketing primarily supporting the EMEAC region.
Prior to joining Merck, Peter worked for Price Waterhouse in their New York City office and for the Financial Accounting Standards Board in Connecticut.
Peter received his Masters in Business Administration from Lehigh University and his Bachelor of Science in Business Administration from Bucknell University.
Peter holds a CPA license in the State of New York.
_____________________________________________________________________________________________________________________________
|
|
|
|
Beth Autin
Manager, Library Services
Gen-Probe
Beth Autin has over ten years of experience in the Pharmaceutical, Medical Diagnostic/Biotech, Chemical and Legal industries. She has been Manager of
Library Services and Information Management at Gen-Probe Incorporated since March, 2005. In this broad role, she has established the Corporate Information
Center, providing centralized information services to colleagues in R&D, Marketing, Strategic Planning, Business Development and Operations. In addition to
providing traditional library services, business and competitive intelligence, she led the team to redesign the corporate intranet, playing an integral role in the
layout, design and search functionality.
Prior to Gen-Probe, she worked at Pfizer Global Research and Development and Ligand Pharmaceuticals, both in the San Diego area. She is a member of
the Special Libraries Association, Pharma & Health Technology and Business & Finance Divisions. She holds a B.A. in Art History and Master of Library and
Information Science from Louisiana State University.
_____________________________________________________________________________________________
|
| |
|
Jean-Remy Behaeghel
Director, Clinical and Regulatory Solutions
Vertex
Jean-Remy Behaeghel is Director, Clinical and Regulatory Solutions in the Global Information Services group at Vertex. In his current role, Jean-Remy
oversees the definition and deployment of the technology strategy supporting the Vertex Medicine Development Group. Prior to joining Vertex he held several
leadership positions at Perceptive Informatics, PAREXEL technology division. While at Perceptive he participated in the creation of the IVRS business unit
and later started a product management group to lead Perceptive product and services portfolio strategy. He attended the University of Technology of
Compiegne, France and the Technical University of Berlin, Germany earning an advanced degree in Biomedical Engineering.
_____________________________________________________________________________________________________________________________
|
|
|
|
Stan Bernard
President
Bernard Associates, LLC
Stan Bernard, MD, MBA is the Founder and President of Bernard Associates (www.BernardAssociatesLLC.com), a pharmaceutical and health care industry
management consulting firm that offers strategic planning, marketing, competitive simulations (war games), competitive planning, and business development
services. The firm thrives on the cutting-edge: new products, technologies, services, ventures, markets, customer segments, opportunities, challenges, and
issues. Bernard Associates has worked with nine of the top ten pharmaceutical companies and many of the leading biopharmaceutical, medical device,
diagnostics, and health care products companies.
Dr. Bernard is nationally recognized as a health care and pharmaceutical industry consultant, speaker, and author. He has been featured on national
television and in leading publications, including the Wall Street Journal, Business 2.0, and Business Week. He has published over 50 book chapters and
articles on health care and pharmaceutical topics.
Previously, Dr. Bernard served as a Principal in the Health Care and Pharmaceutical Industry Consulting Practice at A.T. Kearney. Prior to joining A.T.
Kearney, Dr. Bernard worked at Bristol-Myers Squibb Pharmaceutical Company where he held several executive business and medical positions. He served as
U.S. Product Manager for the launch of the cholesterol-lowering drug Pravachol, Bristol-Myers Squibb’s most successful pharmaceutical product. He served as
U.S. Managed Care Medical Director, the first person to hold such a position in the pharmaceutical industry, and as U.S. Director - Pharmacoeconomics.
Previous positions included those in Worldwide Business Development, U.S. Medical Operations, and U.S. Medical Services.
Dr. Bernard is a former Senior Fellow in the Health Care Systems Department at The Wharton School of Business where he initiated and taught in the
“Pharmaceutical Management” course for fourteen years. Dr. Bernard is the recipient of the prestigious Wharton School of Business Alumni Achievement
Award for his contributions to Wharton and the health care industry. Dr. Bernard received his M.B.A. in marketing and health care management from the
Wharton School of Business. He received his Medical Degree from Baylor College of Medicine.
_____________________________________________________________________________________________________________________________
|
| |
|
E.B. Brakewood
Exec. Director
Merck Bioventures
_____________________________________________________________________________________________________________________________
|
| |
|
Chris Bogan
CEO
Best Practices
Chris Bogan is the Chief Executive Officer and Founder of Best Practices®, LLC, a leader in the field of best practice performance improvement. Based in
Chapel Hill, North Carolina, Best Practices®, LLC specializes in providing pharmaceutical, biotechnology and medical device corporations throughout the
world with business intelligence, research, benchmarking studies, and consulting services. The company's products and services provide corporations with
"Access And Intelligence For Achieving World-Class Excellence™."
Mr. Bogan received his MBA with honors from the Harvard Business School and his bachelor's degree magna cum laude from Amherst College. He was a
Nieman Fellow at Harvard University. Mr. Bogan's work has focused on organizational excellence, blockbuster product launches, marketing excellence, sales
force effectiveness, clinical operations and best practice improvement strategies. He has written about numerous aspects of performance excellence and
continuous improvement. In recent years, he has concentrated on ways that companies can use best practice insights to create economic value, accelerate
revenue and profit growth, and drive rapid performance improvement. He is co-author of the widely acclaimed books, Benchmarking For Best Practices:
Winning Through Innovative Adaptation, published by McGraw-Hill, and The Baldrige: What It Is, How It's Won, and How To Use It To Improve Quality In Your
Company.
Mr. Bogan has consulted on performance improvement and best practice competitiveness issues for a wide range of pharmaceutical, biotechnology and
medical device companies, including Pfizer, Eli Lilly, GlaxoSmithKline, Genentech, J&J, Amylin, Sanofi-Aventis, AstraZeneca, Amgen, Novartis, Roche,
Baxter Healthcare, Bayer, 3M Pharmaceuticals, Abbott Laboratories, Astellas, LifeScan, Guidant, Janssen Pharmaceutica and others.
Mr. Bogan led the consulting teams that assisted both Federal Express and GTE Directories (now Verizon) in winning the prestigious Malcolm Baldrige
National Quality Award. He has also advised many leading corporations outside the healthcare sector, including industry leaders such as Microsoft, American
Express, AT&T, General Motors, BellSouth, Chevron, Exxon, Xerox, Verizon, Marriott, Merrill Lynch, Siemens, KPMG, the New York Times Company, J.P.
Morgan Chase & Co., TIAACREF, Nortel Networks, Pitney Bowes, Bank of America, Wachovia and many others.
A guest lecturer at Northwestern University’s Kellogg School of Management and the University of North Carolina’s (UNC) Kenan Flagler Business School, Mr.
Bogan has spoken widely before business audiences in North America, Europe, Asia and Latin America. He is an advisor to various management magazines on
best practice and management issues. He currently serves on the UNC Academic Leadership Institute’s National Advisory Board. Previously, he served on the
Board of Directors of Ontogeny, Inc., a stem cell and functional genomics company now named Curis, Inc.
Prior to founding Best Practices, LLC, Mr. Bogan was a principal and founding member of The TQM Group, Ltd., a Bostonbased consultancy. Mr. Bogan also
spent many years working at various media companies, including Times Mirror Corp., Knight-Ridder Inc., Howard Publications and Cowles Publishing Co. He
has contributed articles to many newspapers and magazines, including The Harvard Business Review, Time, Pharmaceutical Executive, PharmaVoice,
MedAd News, Planning Review, The Los Angeles Times, The Boston Globe, The Miami Herald, The Chicago Tribune and The Philadelphia Inquirer.
Through his work, Mr. Bogan has toured manufacturing and service companies throughout the world.
_____________________________________________________________________________________________________________________________
|
|
|
|
Branimir Brankov, M.D., M.B.A.
Sr. Director Strategic Business Intelligence
Merck & Co., Inc.
Dr. Branimir Brankov is a professional manager and marketer with a medical and business background and more than 15 years experience in the
pharmaceutical industry.
Dr. Brankov is currently responsible for Strategic Business Intelligence Group which is part of the Global Competitive Intelligence Unit established in the Merck
Headquarter in Whitehouse Station, N.J., U.S.A. In this capacity, his main functions include managing global projects and initiatives, conducting competitive
analysis and providing guidance to Merck Executives and Global Marketing Teams on strategy development.
In his previous roles at Merck, Dr. Brankov has been Global Leader for Physician Communities of Practice initiative at Merck. As part of the Global market
research team in Merck Headquarter he has been responsible for providing global market research and business intelligence support for several therapeutic
areas. Before his assignments in Merck Headquarter Dr. Brankov was responsible for establishing and managing independent subsidiaries for Merck & Co., Inc.
in Bulgaria, Macedonia and Albania.
Dr. Brankov received his M.D. from the Medical University of Sofia and practiced at the Military Medical Academy in Sofia, Bulgaria, specializing in
Neurosurgery. In 2001, he obtained a Masters’ Degree in Economics from the Economics University of Sofia, with concentration in Human Resources; and, in
2003, he earned a Masters’ Degree in Business Administration from Rutgers University, New Jersey, with concentration in Marketing and Management. He is
active member of PBIRG, SCIP and MRII.
_____________________________________________________________________________________________________________________________
|
| |
|
Millie Cason
Associate Director, Competitive Intelligence
Astellas Pharma US
Millie Cason is the Associate Director of Competitive Intelligence for Astellas Pharma US . Ms. Cason has over 15 years of experience in competitive
intelligence, strategy and decision support for companies including Astellas, Amgen and Abbott.
In current and previous roles, Ms. Cason has spearheaded the establishment of the competitive intelligence function. She has extensive experience and
success in developing and implementing early warning systems, business war games and global monitoring programs that support brand management,
marketing, regulatory and R&D functions.
_____________________________________________________________________________________________________________________________
|
| |
|
Michelle Castillo
Director of Competitive Intelligence
Baxter Corporation
Michelle Castillo is Director Of Competitive Intelligence for Baxter Healthcare. Ms. Castillo has over 15 years of experience within strategy, business
intelligence, and market research in pharmaceuticals/biologics, devices, and diagnostics. Ms. Castillo is currently responsible for Baxter Pharmaceutical
Technologies’ global competitive intelligence, a $1.5B business unit within Medication Delivery. Ms. Castillo has been with Baxter for 5 years and led the
establishment of the competitive intelligence business function. Responsibilities include strategic intelligence on commercial, manufacturing, and clinical
activities of competitors and is actively involved with domestic and international commercial, business development, manufacturing, and clinical operations.
Prior to joining Baxter, Ms. Castillo worked in pharmaceutical and device consulting with Decision Analyst, Inc. and The Mattson Jack Group. Ms. Castillo
holds a MBA from Baylor University and BS from Columbia College.
_____________________________________________________________________________________________________________________________
|
| |
|
Deborah Dauber
Associate Director, Competitive Intelligence
Genentech USA, Inc.
Deborah has been with the Genentech Competitive Intelligence group for the past five years, supporting decision making for both R&D and Commercial teams.
As an individual contributor and later as the lead for the Immunology team, Deborah led competitive intelligence initiatives to investigate key competitors
(product and company-level), evaluate revenue impact of competition, and assess full market landscapes. Deborah has led Competitive Intelligence at
Genentech (as interim head and later as Associate Director) since 2007. Prior to joining Genentech, Deborah was a Consultant with WWMR, Inc., where she
worked with clients to design and execute market/opportunity assessments and managed the analyst team on custom projects. She has a B.S. in
Chemistry/Cellular and Molecular Biology from the University of Michigan, Ann Arbor, and a Ph.D. in Chemistry and Chemical Biology from the University of
California, San Francisco.
_____________________________________________________________________________________________________________________________
|
|
|
|
Raj Dave
Head of U.S. Operations
PharmARC Analytic Solutions
Raj has over 20 years of experience in the pharmaceutical and healthcare industries. His career includes leading business analysis, market research, strategic
planning and business development functions for multinational pharmaceutical (Bristol-Myers Squibb), specialty pharmaceutical (Ferring), pharmacy benefit
management (Medco) and start-up biotechnology companies (WellGen).
_____________________________________________________________________________________________________________________________
|
| |
|
Jamie Denison-Pender
Managing Director
CIS Lifesciences
Jamie is the Managing Director of CIS Life Sciences, a global CI consultancy specializing in primary intelligence gathering, secondary due diligence,
analysis and consultancy within the pharma, biotech, generics and medical device markets. Jamie joined CIS back in 1997 and prior to that was an analyst
with a European strategic consultancy specializing in the energy and construction markets.
At CIS he’s been responsible for growing the business organically through a continuous enhancement of the offerings – focusing on marrying the skill sets of a
traditional CI agency with those of a strategic consultancy.
Jamie has a BSc in Mechanical Engineering and Business Studies from Oxford Brookes University.
_____________________________________________________________________________________________________________________________
|
|
|
|
Carl Derenfeld
Vice President, Strategic Solutions – Healthcare
Proactive Worldwide, Inc.
Carl provides a distinctive 360-degree perspective spanning all aspects of global healthcare. Over his 30-year career, he has served within for- and not-for-profit
entities as well as a clinical practitioner. He has looked over the shoulders of dozens of clients of all sizes, assisting them with making evidence-based business
decisions, prioritizing emerging market threats and opportunities, and identifying hotspots. In doing so he has developed a rich perspective and the ability to
provide a semantic layer to interpret the challenges and opportunities of the current and future healthcare environment. He is known as a renaissance
professional with a demonstrated knack for marrying historical perspectives with a strong forward sense of predictive vision.
Carl’s hybrid background has been built by integrating the disciplines of general management, consulting, strategic planning, business development, lifecycle
maximization, marketing, sales, e-business, competitive intelligence, research & development, patient recruitment, publications, standards setting,
medication error reporting, advertising, high-tech software data analysis, and emerging healthcare systems and global communities.
Carl has held progressive management positions with Proactive Worldwide, Inc., a leading global competitive intelligence and strategic consulting firm, where
he is currently Vice President, Strategic Solutions – Healthcare. He most recently served as the Principal Director and Life Sciences/Healthcare Domain
Expert for Verix, Inc., an innovative high-tech software firm whose engine provides unguided revelation of hotspots and extraordinary findings at focal points in
the data. He previously held senior positions with Marketing Technology Solutions (MTS) (QualityHealth.com), AmericasDoctor/Essential Group CRO/Patient
Recruitment, the United States Pharmacopeia (USP), Pharmacia/G.D. Searle, Boots Pharmaceuticals, Flint Laboratories (Baxter Corporation), Health Systems
Projects, Dimensional Marketing/Advertising and Lead Consultant at Derenfeld and Associates Consulting.
He holds a Master's in Business Administration from Northwestern University (the J.L. Kellogg School of Management) and a Master's of Social Work from
Yeshiva University (the Wurzweiler School). He received his BA from SUNY at Stony Brook. Mr. Derenfeld is a member of the J.L. Kellogg Alumni interviewing
team and the Gerson Lehrman and DeMatteo Monness consulting groups.
_____________________________________________________________________________________________________________________________
|
|
|
|
Richard DiCicco
CEO
Harvest Moon Pharmaceuticals
Richard DiCicco co-founded Harvest Moon Pharmaceuticals by acquiring the pipeline of TCI Generics, a subsidiary of the renowned Technology
Catalysts founded by Mr. DiCicco in 1979. Harvest Moon Pharma develops high barrier to entry generic drugs and biosimilars. Currently there are 35
P-IV ANDA products in the Harvest Moon Pharma pipeline. In biosimilars, Harvest Moon Pharma is commercializing EPO-alpha, beta-interferon 1a and
1b, peginterferon alfa-2b, imiglucerase, filgrastim, pegfilgrastim, r-hu-insulin, glargine, lispro, etanercept, trastuzumab, rituxumab, bevacizumab,
cetuximab and adalimumab). Mr. DiCicco is a member of the Editorial Board of the Journal of Generic Medicines, a member of the Licensing Executives
Society, and is widely published in generics and biosimilars.
___________________________________________________________________________________
|
|
|
|
James Down
Vice President of Research & Development
Becton Dickinson & Co
Dr. James Down is a business leader with a blended scientific and business background and 20 years experience in the development of technologies and
products for the medical device and diagnostic industries.
Dr. Down is currently responsible for the design, implementation and management of BD’s global Product Lifecycle Management system, centered at BD’s
headquarters in Franklin Lakes, New Jersey.
Previous positions held by Dr. Down include Vice President, Research and Development for BD Preanalytical Systems, where he was responsible for leading
the development of new products for the company’s blood collection business. In this role he oversaw the launch of numerous successful and innovative
products. Prior to that, Dr. Down was the Director of Business Development at BD Technologies, the company’s technology development center located in
Research Triangle Park, North Carolina. As part of that role, he managed the company’s business incubator which at the time accelerated the growth of
approximately ten emerging companies with total accumulated funding of approximately two hundred million dollars. He also led the establishment of the
Singapore Bioventure Center, in partnership with the Singapore Economic Development Board and Johns Hopkins University. In previous technology roles, Dr.
Down led teams in the development of innovative technologies and products for drug delivery (iontophoretic, transdermal and microneedle devices) as well as
molecular diagnostic testing (e.g. BD ProbeTecTM). Prior to that he was a Research Fellow at Harvard University, where he studied the x-ray crystal structures
of surface proteins from trypanosomes, the causative agent of African sleeping sickness.
Dr. Down holds degrees in Biology (BSc, U. Victoria), Physiology (MSc, Dalhousie U.) and Biochemistry (PhD, U. Toronto) as well as business certificates from
the Kenan Flagler Business School (U.N.C). He is an inventor on twenty-one US patents and is an author of more than thirty research articles, book chapters
and presentations.
_____________________________________________________________________________________________________________________________
|
|
|
|
Sandipa Dublish
Director, Global Market Research
Eisai
Sandipa Dublish is Director, Global Market Research at Eisai Corp. In this role she manages all aspects of strategic business insights including
Competitive Intelligence. In her previous position as Director, Oncology Market Research with Bristol-Myers Squibb – Sandipa was an active user of
Competitive Intelligence. She therefore has a unique perspective on CI both as a provider and a user.
Sandipa holds a PhD. in Marketing from Florida International University and an MBA from Faculty of Management Studies, Delhi, India.
_____________________________________________________________________________________________________________________________
|
|
|
|
Neelima Firth
Vice President Healthcare Markets
Fletcher/CSI Healthcare Strategies
Neelima Firth is an experienced biopharmaceutical executive with extensive scientific, reimbursement, marketing and international experience in start up and
Fortune 500 biopharmaceutical companies including GSK, Bristol Myers Squibb, Sandoz and Amgen. As VP Healthcare Markets at Fletcher/CSI Healthcare
Strategies, Neelima influences strategic and tactical direction for Fletcher/CSI’s Managed Markets and General Healthcare practices. Working closely with
clients in the pharmaceutical and payer environments, Neelima is integral in designing and implementing effective competitive client market penetration
programs.
Previously, she was the Director of Strategic Planning and Operations at Amgen and led the strategic planning and operations group and worked closely with
the competitive intelligence group in gathering critical business information to aid informed decision making.
She worked at Amgen for 16 years in a series of increasingly senior roles in clinical, marketing and reimbursement in the UK and USA. Accomplishments
includes developing compendia strategy, managing Medicare and Medicaid marketing strategies, creating alliance management governance and
managing clear brand planning processes. She was instrumental in building the initial UK/European presence of Amgen to support the launch of new products.
In England, she was the President of AIOPI- Association of Information Officers in the Pharmaceutical Industry. She is a board member of the Association for
Strategic Planning in LA.
She has an Information Science degree from Leeds Metropolitan University in England, a Certificate in Legal Studies from Cambridge University in England
and an MBA from Pepperdine University in the US.
_____________________________________________________________________________________________________________________________
|
|
|
|
Carolyn J. Foster
Sr. Associate Director, Technology Assessment
Boehringer Ingelheim Pharmaceuticals, Inc.
Dr. Foster joined Boehringer Ingelheim Pharmaceuticals in 2001 and now heads the Competitive Technical Intelligence group for cardiovascular and
autoimmune diseases. In that capacity, she analyzes the external environment in the context of internal business issues, especially where technology is a
factor. Her internal clients include R&D, Marketing and Medical management and the analysts that support them.
Prior to her CTI career, Dr Foster spent 20 years as a biochemical pharmacologist in Cardiovascular Drug Discovery at Schering Plough working on drugs to
treat hypertension, atherosclerosis, thrombosis, and Parkinson’s Disease. Her published research focuses on G-protein coupled receptors and platelet function.
Dr. Foster studied chemistry at Swarthmore College, received an M.S. in biochemistry from Brown University and a Ph.D. in pharmacology from the University
of Medicine and Dentistry of New Jersey. She did post-doctoral research at the University of Pennsylvania in human genetics. She is a Fellow of the New York
Academy of Sciences where she has served as a member the conference planning committee, as Chair of the Biochemistry Section, and as head of the
Biochemical Pharmacology Discussion Group, an academia-industry consortium.
_____________________________________________________________________________________________________________________________
|
| |
|
Robert Franc
Director of Competitive Intelligence
Lifescan
Robert Franc has over 26 years of Competitive Intelligence Experience; 12 years working for the US Government and 14 years in the pharmaceutical industry.
He has developed CI programs in the US, Europe, Asia & the Middle East. During his 14 years in the pharmaceutical industry, he has supported R&D and
commercial organizations, both in the US & Europe.
_____________________________________________________________________________________________________________________________
|
|
|
|
Niall Fraser
Founder and Principal Scientist
Open Options
Dr. Niall Fraser has led hundreds of strategy engagements helping the world’s largest corporations hone their decision-making and achieve their best attainable
outcome. Dr. Fraser is a former full professor of Management Sciences at the University of Waterloo and has published four books and over 150 academic
papers on applied game theory. As Founder and Principal Scientist for Open Options Corporation, his advice has been sought by successful business leaders
over a 13-year period on five continents. He has deep experience in commercial, political and military applications of game theory including applications in
competitor positioning, regulatory affairs, and product portfolio management in the pharmaceutical industry.
_____________________________________________________________________________________________________________________________
|
| |
|
Gregory Frykman
Executive-In-Residence
Cleveland Clinic Innovations
Gregory K. Frykman, M.D. is Senior Vice President, and Pharmaceutical and Biotechnology Policy Analyst formerly of the Stanford Washington Research
Group in Washington, D.C. With Mr. Glenn Gruett, Dr. Frykman co-founded Framework Therapeutics, LLC, a pharmaceutical company focusing on the
development and commercialization of sodium aluminosilicate, in 2003. He received his medical degree in 1992 from the Loma Linda University School of
Medicine and his internship and residency in Internal Medicine were both completed at the Los Angeles County – University of Southern California Medical
Center in Los Angeles, California.
Dr. Frykman completed a combined fellowship in Hematology and Medical Oncology at the Johns Hopkins School of Medicine in Baltimore in 1998 and
furthered his grounding in pharmaceutical product development as a recipient of the Cancer Research Training Award, National Cancer Institute (NCI) to study
antineoplastics development at the joint NCI-FDA program during 1998-2000. Following the training award, Dr. Frykman served as a Medical Officer in the
Division of Oncology Drug Products, Center for Drug Evaluation and Research, FDA, and in late 2002 he joined the Washington Research Group, a team of
policy analysts focusing on regulatory and policy issues affecting pharmaceutical and biotechnology industries. Dr. Frykman is the recipient many honors
and awards career such as the American Cancer Society’s Oncology Career Award, the Cancer Research Training Award, National Cancer Institute, a Service
Award, FDA, a Team Excellence Award, FDA most recently being named a Top Up and Coming Biotechnology Analyst by Institutional Investor in 2005.
Dr. Frykman served most recently as a House Officer, Department of Medicine, University Specialty Hospital, has Medical Licensure in the State of California,
and the State of Maryland; and is a Series 7-registered representative under the National Association of Securities Dealers. Dr. Frykman is board certified as a
Diplomate, National Board of Medical Examiners; Diplomate, American Board of Internal Medicine (1995-2005); Diplomate, American Board of Hematology
(1998 – 2008); and Diplomate, American Board of Medical Oncology (1999 – 2009).
_____________________________________________________________________________________________________________________________
|
|
|
|
Leonard Fuld
President
Fuld & Co.
Leonard Fuld is founder and president of Fuld & Company and a pioneer in the field of business intelligence. Mr. Fuld has created many of the intelligence-
gathering techniques and business intelligence concepts used by the world's largest companies.
Mr. Fuld has written four books: The Secret Language of Competitive Intelligence (Random House, 2006), The New Competitor Intelligence (Wiley, 1995);
Monitoring the Competition: Find Out What's Really Going On Over There (Wiley, 1988); Competitor Intelligence: How to Get It – How to Use It (Wiley, 1985),
and The Fuld War Room
CD-ROM (Iron Horse Multimedia, 1998). His articles have been widely published in the business press, including The Harvard Business Review, The Wall Street
Journal, Marketing News, Directors & Boards, Boardroom Reports, Chief Executive, Working Woman, Chief Information Officer Journal, Canadian Business
Review, and The Journal of Business Strategy.
Mr. Fuld delivers public and private seminars on intelligence principles and techniques to business executives around the world. He has addressed numerous
conferences, including the American Marketing Association, the Conference Boards of New York and Canada and the Planning Forum. In the summer of 1991,
over 400 of Brazil's top executives attended a special business intelligence conference held in Sao Paulo featuring Mr. Fuld. And in fall of 1991, Mr. Fuld was
invited by the United Nations Industrial Development Organization (UNIDO) to join a small group of experts from around the world in a roundtable discussion on
techno-economic intelligence in Vienna, Austria.
Mr. Fuld also consults with corporations on the development and expansion of their intelligence programs.
_____________________________________________________________________________________________________________________________
|
|
|
|
Nikki Gainey
Director of Global Business Analysis
GE Healthcare
Ms. Gainey joined GE in 2006 and now heads the Competitive Intelligence Group for GEHC. Before working at GE, Nikki worked for GSK, GlaxoWellcome,
Deloitte Consulting and Westfield Companies. Her experience ranges from information Management and healthcare consulting to a variety of functions in
marketing, market research and competitive intelligence.
Nikki earned her MBA in Innovation Management and New Product Development from North Carolina State University, She also holds a Bachelor's degree in
Biology, Environmental Studies, and Public Relations from Ohio Northern University.
____________________________________________________________________________________________________________________
|
|
|
|
Monika Giese
Former Head of Global CI
Novartis Pharma AG
Monika has worked for more than 25 years in the Pharmaceutical Industry, primarily at the HQ of global companies such as GSK, Novartis, Hoffmann –
LaRoche etc. She has rich experience in the area of Information and Knowledge Management, Market Research, Business Analytics, Forecasting and
Competitive Intelligence. In recent years she has specialized her activities on Strategic Competitive Intelligence , supporting all areas of C-Suite decision
making and Strategic Planning, mainly for projects in Marketing, Business Development, Mergers & Acquisitions and Organizational Benchmarking &
Resturcturing.
Monika has been a member of SCIP (Society of Competitive Intelligence Professionals) and the Strategic Leadership Forum (ILF) for many years, thus
becoming globally one of the most desired speakers and teachers in the field of Strategic Competitive Intelligence. Monika has recently resigned from her role
as the Head of Global Competitive Intelligence at Novartis Pharma AG to pursue a career as a consultant and advisor, mainly supporting and coaching
organisations to build effective internal CI organizations .
A scientist with an interdisciplinary background, Monika holds a BS degree from the University of Bochum , Germany in Neurophysiology, Immunology, and
Biochemical Pharmacology. She also is a certified CI professional and Market Researcher, holds an International Marketing and Communications degree from
the Nijenrode Business School, and the London Business School.
_____________________________________________________________________________________________________________________________
|
| |
|
Erik Glitman
Managing Director
Fletcher/CSI, LLC
Erik Glitman is a founder and Managing Director of Fletcher/CSI and serves as the Director of Global Operations, Research, and Strategy. As a founder of
Fletcher/CSI, he has been active in the Competitive Intelligence industry for over 15 years. He has worked with clients in areas such as automotive, electronics,
Healthcare, IT, kitchenware, machinery, pharmaceuticals, and Telco.
As an active part of the Fletcher/CSI consulting practice, Erik has extensive experience in working with clients to help them gain competitive advantage in the
marketplace through the integration of qualitative and quantitative CI collected from global sources. Fletcher/CSI, headquartered in Williston, VT, has been
active in the international CI marketplace since its inception and operates with 22 affiliate offices world-side. International clients use Fletcher/CSI consulting
services to understand competitor positions and develop strategies to increase profitability. A global leader in ethical CI, Fletcher/CSI has a history of accurate
and timely analysis on competitive situations while working with clients to develop effective strategies in rapidly changing markets.
Erik holds a B.S. degree in Economics from the University of Vermont, a B.S. in Environmental Studies from Johnson State College, and an M.S. in
International Affairs from American University. He is active with local charities and serves on the board of the Vermont Multiple Sclerosis Society Bike Tour, to
be held in August of each year.
_____________________________________________________________________________________________________________________________
|
|
|
|
Jason Grillo
Manager, Strategic Marketing
Exelixis, Inc
Jason Grillo is a Manager in Strategic Marketing at Exelixis Inc. He is the primary lead for competitive intelligence analysis at the company, encompassing
conference related CI efforts as well as CI analysis sourced from primary and secondary research. This work reaches CI users at both the upper management
and project team level across the organization, focusing on product development for an oncology portfolio. His other responsibilities include forecasting,
market opportunity assessment and patient advocacy management. Prior to Exelixis, Jason worked as a strategic consultant at Navigant Consulting, Inc, and in
various positions at Biogen, Inc. Jason holds an MBA from the Fuqua School of Business at Duke University and an AB from Harvard University .
_____________________________________________________________________________________________________________________________
|
|
|
|
Elisabeth Hefti
President
Biotech Business Link
Dr. Elisabeth Hefti is the founder and principal consultant of Biotech Business Link, a consulting group that specializes in business intelligence and technology
evaluations. Dr. Hefti has a thorough understanding of life sciences and she has more than 20 years of business experience, evaluating the commercial
potential of scientific discoveries. Prior to starting Biotech Business Link, she held corporate positions directing biotechnology R&D efforts and assessing
related investment opportunities.
During the past 18 years, Biotech Business Link helped corporate executives to gain a better understanding of the competitive landscape and/or new product
developments. The clients include top 10 pharmaceutical companies, established and emerging biotechnology companies, and financial institutions.
Biotech Business Link provides fact-based knowledge, validated by primary sources, to guide critical business decisions.
Dr. Hefti is multilingual (English, German, French), and due to her Swiss background has a strong appreciation for cultural differences. She earned a Ph.D. in
biochemistry from Rutgers University and an MBA in finance from the University of Chicago.
_____________________________________________________________________________________________________________________________
|
| |
|
Dave Hitchcoff
Vice President Consulting Services
Dunn Group
David Hitchcoff is Vice President of Consulting Services at The Dunn Group, Inc (TDG). David also serves as Global Team Leader on selected competitive
intelligence projects. He has been with TDG for over eight years and has managed over 50 projects. One of his global teams simultaneously deployed ten
primary Research Analysts, a Medical Director and Pharmacology Advisor.
David has developed numerous project management tools and techniques to synchronize intelligence research and information development with information
requirements (Key Intelligence Topics) these processes have been presented at professional development seminars such as the N.J. Society of Competitive
Intelligence Professionals Education Day. He has also attended over 100 medical conferences and has drawn upon this experience to develop the
methodology presented at the Fourth Annual Pharma & Biotech Business Intelligence Summit and the 2005 Pharmaceutical Business Intelligence Research
Group Annual General Meeting in 2004.
David worked closely with outside counsel to develop the TDG C.I. Collection Guidelines and has informally advised numerous clients in this area in addition
to authoring an article on the subject for Regulatory Affairs Focus the Journal of the Regulatory Affairs Professional Society.
Prior to joining TDG, David held numerous executive positions during twenty-five years in the medical device and instrumentation sector including:
- V.P. Sales and Marketing at Colin Medical Instruments (CMI)
- Director of Regulatory Affairs at CMI
- Director of Cardiovascular Instrumentation at Gould Corporation
- Director of Marketing at Datascope Corp.
A native of New Jersey, David’s various assignments have taken him to Southern California, Northern California and Texas. He and his family currently reside in
Montville, New Jersey.
_____________________________________________________________________________________________________________________________
|
|
|
|
Richard Horowitz
Attorney-at-Law
Richard Horowitz & Associates
Richard Horowitz is an attorney concentrating in corporate, international, and security matters. He is admitted to practice law in New York and the District of
Columbia and has passed the Israeli bar examinations. Mr. Horowitz is also a licensed private investigator and a recognized expert in the areas of corporate
intelligence, fraud, and international investigations.
He is also the author of the Society of Competitive Intelligence Professional's (SCIP) Policy Analysis on Competitive Intelligence and the Economic
Espionage Act, has advised SCIP on the revision of its Code of Ethics, and is on the faculty of the Fuld Gilad Herring Academy of Competitive Intelligence
where he lectures on the legal aspects of competitive intelligence.
Mr. Horowitz holds a B.A. in political science from Yeshiva University, an M.A. from the Department of Politics of New York University studying international
relations, a Mortimer Zuckerman Fellowship at Columbia University's Graduate School of International and Public Affairs, and a J.D. from the Benjamin N.
Cardozo School of Law.
_____________________________________________________________________________________________________________________________
|
| |
|
Chris Hote
CEO
Digimind
Chris Hote is President of Digimind Inc. In his role, Hote works with organizations of all kinds to develop their intelligence framework to monitor, detect and
interpret change in their business environment. Hote also defines the strategy for easing adoption of competitive intelligence products throughout the CI
community.
Hote joined the Society of Competitive Intelligence Professionals in 2008 and participates in SCIP New England chapter. Previous to joining the Digimind
company Hote participated in multiple high-technology companies. Lastly, Hote co-founded the PolySpace start-up company focusing on the embedded
software market that got acquired by The MathWorks: a great experience to understand the role of competitive intelligence as an executive practitioner.
Hote has a PhD in physics, an MBA from Toulouse university and is a fellow student from MIT Sloan.
_____________________________________________________________________________________________________________________________
|
|
|
|
David Johnson
Device Assembly Technology Engineering Manager
Medtronic
I am a manager responsible for research and development of new manufacturing technology for implantable medical devices. I have more than 15 years
experience in research and development technology for manufacturing applications. The past 5 years have been with Medtronic to strategically align future
device manufacturing methods with new designs throughout CRDM technology departments.
___________________________________________________________________________________________________________
|
|
|
|
Cliff Kalb
President
C. Kalb & Associates
Clifford Kalb currently serves as Vice President, Life Sciences at Wood Mackenzie, Inc.
In this capacity he provides thought leadership on industry issues and supports their knowledge based research and consulting practice.
Mr. Kalb has over thirty five years of experience in the pharmaceutical industry. Previously, he served as Senior Director, Strategic Business Analysis, in
Worldwide Human Health Marketing at Merck & Co., Inc. Prior to that, he held positions of increasing responsibility in sales, market research, health
economics, public policy management, marketing management, licensing, business intelligence and business development at Marion Labs, Pfizer and
Roche. He has also served as head of marketing and business development for a small biotechnology company.
Mr. Kalb has served as Chairman of the Conference Board Council on Competitive Analysis. He is also Past President of the board of directors of the Society of
Competitive Intelligence Professionals (SCIP), and Past President of the Pharmaceutical Business Intelligence and Research Group (PBIRG). Mr. Kalb is
widely published in the field of pharmaceutical industry intelligence and analysis.
In 2004, he was made a Fellow in SCIP, and received the Lifetime Achievement Award from PBIRG. In 2005, he was named one of top 100 most inspiring
people in the pharmaceutical industry by Pharmavoice magazine. Mr. Kalb holds a Bachelor’s degree in Biology and Psychology from Rutgers University, and
an MBA in Pharmaceutical Marketing and Economics from Fairleigh Dickinson University.
_____________________________________________________________________________________________________________________________
|
| |
|
Nancy Klein
Competitor News Information
GlaxoSmithKline
_____________________________________________________________________________________________________________________________
|
| |
|
Paul Korathu
Assistant Director, New Product Commercial Analysis
Astellas Pharma US, Inc.
Mr. Korathu has been with Astellas since 2006. His responsibilities include articulating the business logic and commercial insights which influence R&D
investment, partnering, and strategy decisions to senior management teams. Paul joined Astellas from Eisai, where he was Senior Manager, Business
Development. Before Eisai, he worked in academic technology transfer at the University of Minnesota and in basic research at Case Medical School .
Paul earned his MBA in Finance from the Yale School of Management. He also holds a Master’s degree in Biochemistry from The Ohio State University, and
studied the same subject as an undergraduate at Duquesne University .
_____________________________________________________________________________________________________________________________
|
| |
|
David Kuczenski
Director of Strategic Market Intelligence
Lifescience Dynamics (USA)
David is Director of Strategic Market Intelligence at Lifescience Dynamics where his focus is on competitive intelligence and strategic planning. He has
worked, along with his colleagues at Lifescience, for many the largest brands facing loss of exclusivity. He has provided competitor insights and strategic
planning services in support of late lifecycle management strategy in all major markets, last year alone collecting and analyzing CI on generic company
activities from over 40 markets worldwide, including a wide array of emerging markets. He has a Masters in health care policy and management from Columbia
University and has been engaged with Pharma from the supplier side for the past 8 years.
_____________________________________________________________________________________________________________________________
|
|
|
|
Steve Levy
Managing Director
Fletcher/CSI, LLC
Steven heads up the Competitive Intelligence Integration Practice for Fletcher/CSI’s Pharmaceutical Sales and Marketing Practice and has worked extensively
with both pharmaceutical, biotech and healthcare organizations in the design and implementation of Competitive Intelligence programs and processes into
their detailing, marketing, and physician/patient awareness programs. Steven has a 20-year back ground in managing global direct and indirect driven
marketing and sales channel networks and is actively involved in the formulation, and on-going design of Fletcher/CSI’s marketing and sales healthcare
research practice. He is a global speaker and workshop instructor on the subject of sales force effectiveness and is a recognized international speaker on
pharmaceutical sales effectiveness. He is an active member of the Society of Competitive Intelligence Professionals, and has been the Chair of the Society’s
Sales & Marketing Intelligence Symposium. Steve is an originator of the Pharmaceutical Business Intelligence Summit and the Clinical Trial Registries
Symposium.
_____________________________________________________________________________________________________________________________
|
|
|
|
Mark Little
Vice President Competitive Intelligence
Covance, Inc.
Mark is currently Vice President, Business Intelligence at Covance Inc. in Princeton NJ. Mark joined Covance in 2002, and has since merged the intelligence
function with the market research function to form a more comprehensive, external-focusing unit at Covance. Before joining Covance, Mark worked in the
pharmaceutical industry with Glaxo, where he led a business-driven competitor intelligence operation that effected decisions related to both R&D and
commercial strategies.
Mark received a BS in chemistry from the University of North Carolina and a Ph.D. in biochemistry from The Ohio State University. Following his doctorate,
Mark received a National Science Foundation fellowship to conduct research at the University of Grenoble, in France.
Mark has been active with the Society of Competitive Intelligence (CI) Professionals, or SCIP, the 5000-membered organization for CI. Mark served as SCIP
President in 2001-2002, and as a Board member, 1998-2003, and is currently a member of the SCIP Education Committee. Mark is also a member of the
Intelligence Leadership Forum, a thought-leading intelligence organization established in 2003.
Mark has given frequent presentations on CI at conferences and business schools, and has authored several articles on the subject.
_____________________________________________________________________________________________________________________________
|
|
|
|
Neil Mahoney
CEO & President
Global Pharma Alliances
Neil Mahoney is currently the CEO and President of Global Pharma Alliance, Inc. (GPAI), a consulting firm focuses on competitive intelligence that supports
companies in the pharmaceutical and biotech industries. He has been consulting for the past 6 years and prior to GPAI he served as the CEO and President of
Global Business Management Concepts, Inc.
Prior to entering the consulting field, Neil served as the Vice President of Competitive Intelligence at Pharmacia (April 2002 to July 2003) and Novartis
Corporation and Novartis Pharmaceutical Division (1990 to 2002). Neil started the competitive intelligence function at Sandoz Pharmaceuticals (ethical
pharmaceutical division of Sandoz Corporation prior to the Ciba-Geigy and Sandoz merger of 1996) in 1990 and he was one of the early pioneers in creating
a CI function within the pharmaceutical industry. Neil rose to the rank of Vice President and Global Head of Competitive Intelligence of Novartis Corporation
level at Novartis. Neil is one of the few CI professionals to reach the Vice President level within the pharmaceutical industry due to his contributions to the
organizations performance during his tenure in this position.
Neil was responsible for supporting nine business sectors for both operational and strategic issues while at the Corporate level within Novartis. He and his small
corporate CI group supported the various business units for intelligence needs or help set up and train CI functions for the various businesses at different
regional and headquarters locations. Neil has an extensive background in training CI professionals. He was also successful in growing the CI functions within
Novartis on a global level.
_____________________________________________________________________________________________________________________________
|
| |
|
Michael Martinolich
Vice President and Senior Consultant
Fletcher/CSI Healthcare Strategies
Mr. Martinolich is the Vice President and Senior Consultant at Fletcher/CSI Healthcare Strategies. He is responsible for leading the company’s management
consulting services for their pharmaceutical and biotech clients. He is an accomplished veteran of the pharmaceutical industry with over 30 years of
experience in many functional areas within pharmaceutical companies. His expertise includes all levels of sales, sales training, marketing management,
business development, business operations, as well as strategic and competitive insight. He has worked at the local, national and global levels and has been
instrumental in pioneering many innovative programs that have been responsible for revenue growth globally.
During his 30 plus year tenure with a Specialty Pharma company, Mr. Martinolich led the creation, implementation and management of a global CI function
that included leading global strategic initiatives and the portfolio optimization process through CI.
___________________________________________________________________________________________________________
|
|
|
|
Craig McHenry
Senior Director, Competitor Insights, Customer & Market Insights
Wyeth
Craig joined Wyeth (formerly American Home Products Corporation) in 1991 and advanced his understanding of the pharmaceutical industry while working in
several business functions. He started in Global Business Development and Licensing before moving to manage the Secondary Research Analysis function.
He has also worked in Marketing Research where he spent two years directing oncology and hematology market research in the Wyeth BioPharma business
unit. Since early in his career at Wyeth, Craig has been involved with competitive intelligence. In 1993, Craig played a key role in forming the first Business
and Competitive Intelligence function, which has evolved over the years into the current group that he directs called Competitor Insights. One of a handful of
groups focused on specific analysis techniques, this group provides CI consulting, expertise, and oversight to brand teams, new product groups, and Senior
Management. Before Wyeth, Craig spent five years at Unisys and holds a M.A. in Computer Science Ed. He has been a member of SCIP since 1993 and is a
graduate from the Gilead-Herring Academy of Competitive Intelligence.
_____________________________________________________________________________________________________________________________
|
| |
|
Vimal Mehta
Chairman and Co-founder
Bioxcel
Vimal is a business development professional with an illustrious scientific and business career spanning 20 years. Prior to founding BioXcel, he was SVP of
Global Business Development at Inpharmatica, Ltd., a London based biotech company specializing in drug discovery and informatics platform technologies.
He also held senior scientific and business development positions at CuraGen Corporation, a CT based genomics and drug development company. Vimal is a
seasoned executive with a strong history of achievement in diverse business transactions with major focus on establishing partnerships with
pharmaceutical/biotechnology leaders. He has successfully established global commercial operations, developed new markets, and built strong
intercontinental client bases. Vimal holds a PhD in chemistry, and was affiliated with The University of Texas, Southwestern Medical Center at Dallas, both as
a postdoctoral fellow and an assistant professor in the Department of Radiology.
_____________________________________________________________________________________________________________________________
|
| |
|
Joanne Mesite
Director, Competitive Intelligence & Pipeline Disclosure
Pfizer
Joanne Mesite is a member of the Competitive Intelligence function within the Strategic Management Group at Pfizer Global R&D headquarters in New
London, Connecticut. The mission of the group is to support Martin Mackay, President of Pfizer Global R&D, as well as other executive management at Pfizer
with relevant and timely analyses of competitor activities that will impact key R&D decisions.
Before joining Pfizer, Joanne was a Project Manager at Nerac Incorporated supporting competitive analysis for clients within the pharmaceutical, food, and
energy industries.
Prior to Nerac, she acquired an extensive drug development background at Boehringer Ingelheim Pharmaceuticals as a laboratory supervisor in both Quality
Control and Analytical Sciences R&D where she won the R&D Vice Presidential Award for efforts in developing a new laboratory to support international
Clinical Trial operations and new drug development projects. Her Competitive Technical Intelligence experience at Boehringer supported both
Cardiovascular and Immunology therapeutic areas as well as development of the CTI International database. Her Business Intelligence experience includes
supporting Flomax and Mobic Marketing teams where she also received various awards by both product teams for her contributions.
Joanne has a degree in both Biology and Chemistry.
_____________________________________________________________________________________________________________________________
|
|
|
|
Marjorie Norman
Manager, Competitive Intelligence
Pfizer Global Research & Development
Marjorie G. Norman is a Senior Manager in Pfizer’s Global Research & Development Information Management department, specializing in providing business
and competitive intelligence to senior R&D management. Prior to joining Pfizer in 2002, she was Director – Pharmaceutical Practice, at Fuld & Company, a
competitive intelligence consulting firm and a Senior Market Research Analyst at Johnson & Johnson Professional. Ms. Norman holds an MBA from the
Graduate School of Management at Simmons College and a BA in German and art history from Franklin & Marshall College. She recently returned from a six-
month deployment at Population Services International in Nairobi, Kenya, as part of the Pfizer Global Health Fellows program.
_____________________________________________________________________________________________________________________________
|
|
|
|
James (JJ) Owen, Ph.D.
Director, Scientific & Competitor Analysis
Millennium Pharmaceuticals
With over 6 years of experience in the competitive intelligence field, JJ is an Associate Director leading the Scientific & Competitive Analysis group at
Millennium Pharmaceuticals in Cambridge , MA . The group’s responsibilities include the monitoring of competition from R&D through Commercial and
working on cross-functional initiatives within the company.
Previously, JJ spent several years as an analyst within Business Development at AVEO Pharmaceuticals assisting with market research, public relations,
licensing partnerships and R&D collaborations. Other work experience include a stint with a Knowledge Management function at Millennium Pharmaceuticals
and managing teams of curators/editors while at Proteome/Incyte Genomics.
JJ holds a B.S in Microbiology from Mississippi State University and a Ph.D. in Cell Biology from Vanderbilt University .
_____________________________________________________________________________________________________________________________
|
|
|
|
Valerie Pajak
Senior Manager, Business Intelligence & Analytics
APP Pharmaceuticals
_____________________________________________________________________________________________________________________________
|
|
|
|
Daniel Pascheles
Head, Global Competitive Intelligence
Merck
Dr. Daniel R. Pascheles is Vice President, Global Competitive Intelligence, and is based in Whitehouse Station NJ, at the Global HQ of Merck & Co., Inc.
His responsibilities include providing intelligence regarding business, research and development activities of competitors, as well as participating in, and
contribution to the strategy development process, the target identification for licensing and M&A activities.
Pascheles joined Merck & Co., Inc. early 2005 from Aventis Inc. where he was Vice President and head of Corporate Competitive Intelligence. He has worked
for Aventis and its predecessor company (Hoechst Marion Roussel, Marion Merrell Dow) for 14 years in various positions and locations.
Pascheles studied Pharmacy at the Swiss Federal Institute of Technology in Zurich, Switzerland. He received his Ph.D. in Pharmaceutical Technology from
the same university. He has done additional study at the University of Kansas in Lawrence, Kansas.
Pascheles is Past-President and current Board member of the Pharmaceutical Business Intelligence & Research Group (PBIRG). He is also member of the
Society of Competitive Intelligence Professionals (SCIP) and the Licensing Executive Society (LES).
_____________________________________________________________________________________________________________________________
|
|
|
|
Jonas Pedersen
Executive Director
Deallus
Jonas Pedersén is the Chief Operating Officer for the Deallus Group. Previously he was the Director of Competitive Intelligence at Amgen Inc. In this role he
built a world class CI capacity across Amgen. Jonas also worked in R&D at AstraZeneca as the Competitive Intelligence Manager for the Pain Control Therapy
area.
In academia Jonas was an Assistant Professor and acting Deputy Director at the Department of Musculoskeletal Research, National Institute for Working Life in
Sweden.
_____________________________________________________________________________________________________________________________
|
|
|
|
Christopher Perkins
Senior Manager of Business Intelligence
Roche Diagnostics
Christopher Perkins currently manages the Business Intelligence function for Roche Diabetes Care. Mr. Perkins has a BA (Hamilton College) and an MA (Penn.
State) in Mathematics.
Before coming to Roche, Mr. Perkins worked as a Market Research Manager in IBM’s PC Division. Prior to his current role at Roche, Mr. Perkins was Manager of
Market Research and also held an international assignment in Switzerland as Head of Market Insight and Analysis for Roche’s Insulin Pump business.
Mr. Perkins has had the opportunity to sit on the American Marketing Association’s Advanced Research Techniques program committee and has published in
the SIAM Journal of Numerical Analysis.
_____________________________________________________________________________________________________________________________
|
| |
|
Pablo Prados
Senior Director Scientific Competitive Intelligence
Sanofi-Aventis
Pablo Prados is Head, Senior Director of Scientific Competitive Intelligence at sanofi-aventis. Pablo holds PhDs in Pharmaceutical Sciences from the
University Complutense of Madrid and the University of Tokyo, and received his MBA from Temple University. Pablo worked in Japan for 10 years in the
Pharma industry, holding positions in both R&D and Pharma Operations, such as Regulatory Affairs Manager with Nippon Schering, Strategic Planning
Director with Nippon Roche, New Products & Opportunities Head with Aventis Japan, and Business Analysis Head with sanofi-aventis Japan, before moving to
Paris in June 2007 to his current position.
________________________________________________________________________________________________________________________
|
|
|
|
Samir Raiyani
CEO
Dolcera
Samir Raiyani is the Chief Executive Officer and co-founder of Dolcera, a premier intellectual property and market research services company based out of
Hyderabad, India and Silicon Valley, US. Samir brings more than a decade of leadership in high-tech and knowledge service innovation to the company. At
Dolcera, Samir has helped establish relationships with nearly two dozen of the world's largest companies in life sciences, manufacturing and high tech.
Samir was also the co-founder of MediSpark (iScribe), a mobile healthcare startup that is now part of CVS Caremark Inc., one of world's largest retail pharmacy
and pharmacy benefit chains in the world.
He has been a speaker at several conferences and venues including PIUG (Patent Information Users Group), SCIP (Society for Competitive Intelligence
Professionals), SAPPHIRE and the World Internet Center. He has also co-authored books and articles in areas ranging from intellectual property, visualization,
mobile technology and user interaction.
Prior to Dolcera, Samir was Director at SAP Research in Palo Alto, California. At SAP, Samir helped launch several new initiatives in the areas of metro
wireless networks (WiFi-mesh/WiMax), RFID, sensor networking and mobile multimodality. He was instrumental in setting up partnerships with Intel, Motorola and
several other companies.
He has a Masters degree in Computer Science from Stanford University and an undergraduate degree in Electronics and Communication from Gujarat
University.
_____________________________________________________________________________________________________________________________
|
|
|
|
Chandra Ramanathan
Senior Director, New Business Oncology
Wyeth
Dr. Chandra Ramanathan has been associated with pharmacy academia and pharmaceutical industry for more than 22 years. He has successfully applied
scientific insights to address business issues in oncology, immunology, Neuroscience and gastroenterology. He has extensive experience in Identifying new
licensing/business development opportunities and conducting scientific and commercial due diligence on both compounds and technology deals.
Dr. Ramanathan has contributed to the launch of Orencia (Biologic; Rheumatoid arthritis) and Sprycel (small molecule; Chronic Myelogenous Leukemia) by
incorporating competitive insights in marketing strategy development and execution. He has worked across the product development and commercialization
spectrum from discovery, clinical development to marketing. He has successfully worked in new product planning/product commercialization and has
contributed to the development of clinical and commercial strategy for early and late-stage compounds. He also played a key role in evaluating biosimilars
for potential opportunities and assessing risk for the commercial franchise.
_____________________________________________________________________________________________________________________________
|
|
|
|
Dawn Renear
Vice President, Competitive & Technical Information
Genzyme Corp.
Dawn Renear is Vice President of Competitive & Technical Information at Genzyme Corporation in Cambridge, MA. She oversees two intelligence functions:
Technical Intelligence and Competitive & Market Intelligence. These groups are responsible for providing intelligence to all areas of the corporation, and are
fully integrated into both business and science teams.
Dawn is responsible for integrating intelligence activities into business processes and growing corporation recognition of effective intelligence processes. Also
under her responsibility is the Global Library group.
Prior to Genzyme, Dawn was Manager of Information Services at Integrated Genetics, Inc. and Analyst at the Center for the Analysis of Health Practices,
Harvard School of Public Health. Dawn has over 25 years of experience in the biopharma industry. She holds a B.A. in Art History from the University of
Massachusetts at Amherst and M.S. in Information Science from Simmons College.
_____________________________________________________________________________________________________________________________
|
| |
|
Wayne Rosenkrans
Distinguished Fellow, MIT Center for Biomedical Innovation
Chairman & President, Personalized Medicine Coalition
Chief Applications Officer, SciTech Strategies
VP Strategic Consulting, Fuld & Company
Wayne is a Distinguished Fellow at the Center for Biomedical Innovation at MIT working on healthcare strategy and policy issues related to science and
medicine.&n bsp; He is also Chairman, President and a member of the board of directors of the Personalized Medicine Coalition, a Washington DC based
organization working with government and other agencies on evolving healthcare policy for Personalized Healthcare, and Chief Applications Officer for
SciTech Strategies focusing on scientific competency and capacity development for academia and industry. He is a former Director of External Relations for
the Personalized Healthcare Team and Evidence-based Medicine (EBM) as part of External Medical Relations at AstraZeneca where he had responsibility for
long-range external relations strategy and policy development. He is active on several strategy and advisory boards at different organizations including the C-
Path Institute, Georgetown University, IBM, HP, and the Personalized Healthcare Initiative in the Secretary’s office at Health and Human Services. He has
presented at numerous forums on aspects of personalized healthcare, evidence-based medicine, new development paradigms, and strategy development. He
holds an S.B. in Biology from MIT, a Ph.D. in Cell and Molecular Biology from Boston Univ., and received post-doctoral training in Cancer and Radiation
Biology at the Univ. of Rocheste r. Wayne lives in Malvern, PA, is married with two college-age children, and enjoys teaching martial arts (Tang Soo Do),
restoring antique/classic Fords, and aviation history.
_____________________________________________________________________________________________________________________________
|
|
|
|
Ed Rozenberg
Managing Director and Co-Founder
Dolcera
Ed Rozenberg is a Managing Director and co-founder of Dolcera, a premier intellectual property and market research services company based out of
Hyderabad, India and Silicon Valley, US. Ed brings more than a decade of management in high-tech and knowledge service innovation to the company. At
Dolcera, Ed has helped establish relationships with nearly two dozen of the world’s largest companies in life sciences, manufacturing and high tech. He is an
entrepreneur who has previously co-founded a demand aggregation startup and until recently was a Product Manager for enterprise collaboration software at
SAP Labs in Palo Alto, CA.
Ed has also worked as a management and technical consultant with firms including Mercer Management Consulting and S1 Corporation. Ed has a Bachelor's
Degree in Economics from Harvard College.
_____________________________________________________________________________________________________________________________
|
| |
|
Mary Ann Sarao
Sr. Director, Strategic Business Intelligence
DSM Pharmaceuticals
_____________________________________________________________________________________________
|
|
|
|
Marcus Schabacker
Senior VP & CSO
ConvaTec
Dr. Marcus Schabacker, MD, PhD, joined ConvaTec in October 2006 as its
Senior Vice President of Science and Innovation and its Chief Scientific Officer. During his brief tenure, he has already had a measurable impact on the
organization. In particular, his efforts to restructure and revive ConvaTec’s Product Development and Launch Process have more than doubled ConvaTec’s
pipeline value and earned him the 2009 Best Practice Award from Frost and Sullivan. Dr. Schabacker was also a key player throughout ConvaTec’s recent
divestiture from Bristol Myers Squibb. Additionally, Dr. Schabacker’s extensive knowledge of the European marketplace enabled him to play a major role in
ConvaTec’s September 2008 acquisition and integration of Unomedical, a leading European medical devices company.
Beyond these activities, Dr. Schabacker is overseeing the coordination of major cross-functional business initiatives such as SAP implementation,
manufacturing network optimization, and business growth acceleration efforts. Most recently he established a Business Risk Management Process at ConvaTec.
Dr. Schabacker oversees more than 400 employees in three continents.
Prior to joining ConvaTec, Dr. Schabacker served as Consultant to Spencer Trask, a leading private equity firm with ventures spanning emerging technologies,
communications, and healthcare. He also served as Chief Operating Officer for ISW International, a biotech start-up company. Prior to his startup experience,
Dr. Schabacker served four years as B. Braun Medical’s Corporate Vice President of Research and Development, with additional responsibilities for regulatory
affairs, medical affairs, pre-clinical and clinical research in the US.
Before relocating to the US, Dr Schabacker served at B.Braun’s headquarters in Germany and at Draeger Medical in South Africa.
Dr. Schabacker holds an MD and PhD from The Medical University of Lübeck, Germany and currently resides in Princeton, New Jersey.
___________________________________________________________________________________________________________
|
| |
|
Shefali Shah
Senior Director, Strategic Marketing & Market Analytics
Exelixis, Inc
Ms. Shah has been at Exelixis since May 2006, when she joined as Director of Market Analytics. In this role she manages a team whose responsibilities include
competitive intelligence, long-range planning, and publication strategy. She was previously at Genentech for 4 years, first leading the
Coverage&Reimbursment Policy group, and then leading the Market Planning team for Avastin, and prior to that a Senior Consultant at The Lewin Group in
Washington DC. She holds an MPH from Boston University and a BA from Dartmouth College.
_____________________________________________________________________________________________________________________________
|
|
|
|
Sanjiv Sharma
Vice President of Commercial Affairs
Nicox
Sanjiv Sharma has successful experience both at National and Global levels in Pharmaceutical Marketing, Sales Management, Strategic Planning, Market
Access, and Government Affairs. He has a sound knowledge of pharmaceutical markets and healthcare systems in both North American and Asia. Currently, as
a VP Commercial Affairs, He heads the commercial operations for NicOx SA and He is responsible for implementing a global commercial strategy for NicOx’
portfolio and defining and implementing the strategy for establishing sales and marketing operations in preparation for the launch of naproxcinod, the first
compound in the CINOD class and the Company’s lead product for the treatment of the signs and symptoms of osteoarthritis. Sanjiv is also heads NicOx’s US
operations and is a member of the Company’s Executive Committee. Before joining NicOx, He was head of Strategic Marketing & Business Analysis (SMBA)
function for Biovail Pharmaceutical Inc, USA. In this role, he was responsible for new product commercialization and strategic life cycle management across
five therapeutic areas with a special focus on Wellbutrin XL and Ultram ER franchise: marketing of the current legacy product portfolio.
Before joining Biovail, he worked for Sanofi-Aventis and its predecessor companies for 15 years. During these 15 years, he experienced the success of several
companies’ key brands through various commercial roles, e.g. Cardizem, Lovenox, Altace, Texotare, Amaryl, Lantus and Exubera.
In the Global Marketing role in USA, He led several global cross-functional teams, in a matrix organization involving R&D, business development, brand teams
for USA, Japan and EU. Actively involved or led several strategic endeavors, e.g., Roadmap for Aventis Diabetes leadership; Non injectable insulins strategy:
North American Leadership Strategy; Aventis first Global Dynamic Diabetes Market Model for strategic planning and forecasting multiple opportunities, and
was also involved in several major Business Development deals and partnerships.
At Aventis Canada, He was a member of the Management Committee (PMC) .Led three functional departments within commercial affairs and led or involved
in five products launches.
For his contribution in building innovative healthcare solutions, he was awarded “ The Year 2000 Who’s Who in Healthcare” by Rogers Media, the largest
healthcare publishing group in Canada. He holds MBA with Distinction from Richard Ivey School of Business, University of Western Ontario, Canada, and was
designated as an Ivey Scholar for Scholastic Excellence.
_____________________________________________________________________________________________________________________________
|
|
|
|
James Shen
Publisher
Pharma China
James J. Shen, a veteran of the Chinese pharmaceutical industry and market, has dedicated his entire 21-year career to pharmaceutical businesses in China
and Asia. James Shen started his career in the pharmaceutical industry in 1987 when he joined Beijing Ciba-Geigy Pharmaceutical Ltd. (now Beijing
Novartis) as Assistant to the General Manager. While he studied in England in various periods of 1980s, he worked as an editorial consultant for Scrip/PJB
Publications, IMS and Financial Times Business Information on China’s healthcare news.
In 1991, he founded WiCON International Ltd. in the USA to provide strategic consulting and competitive intelligence to international pharmaceutical
companies in order to assist and facilitate their market entry into China. He has worked with many large and mid-size international pharmaceutical companies
on a diverse range of projects including entry strategy development, strategic alliances and joint ventures, marketing and distribution agreements, product
registration and clinical trials, licensing and technology transfer, API sourcing, and M&A due diligence. His clients included Pfizer, GD Searle, IVAX,
GlaxoSmithKline, Novartis, Sanofi-Synthelabo, TEVA, Taro, Ajinomoto, AL Pharma, IMS, Medical Economics/Thomson Healthcare, Mylan Pharmaceuticals,
Polichem, and Merrill Lynch. In the late 1990s, he consulted exclusively for a few multinational generic pharmaceutical companies, and was responsible for
their business development activities and joint venture projects in Asia-Pacific countries.
_____________________________________________________________________________________________________________________________
|
|
|
|
David Stefanoni
New Products Marketing
Sanofi-Aventis
David Stefanoni is Head of Business Intelligence at sanofi-aventis. He is responsible for managing the BI process for sanofi-aventis in the US and directly
supports key corporate initiatives. David has been in the medical / pharmaceutical industry for 17 years and has experience in the areas of wound care,
infection control, antihypetensives, infectious diseases, pain management, oncology, rheumatoid arthritis, Crohn’s disease, & medical dermatology.
Prior to joining sanofi-aventis in October, 2004, David worked with Centocor, a biotechnology division of Johnson & Johnson. David has a BSBA in Business
Administration from Truman State University and a MSHSA from Southwest Baptist University.
_____________________________________________________________________________________________________________________________
|
|
|
|
Kim Szymanowski
Competitive Intelligence Manager
Ethicon, a Johnson & Johnson Company
Kim Szymanowski has worked at Ethicon, a Johnson & Johnson medical device company for the past 24 years. She has worked in most functional areas
throughout the organization including:
12+ years in Suture, Needle, Packaging and Sterilization Manufacturing
5+ years in New Product Development
3+ years in Resource & Portfolio Management
1+ years in Strategic Planning
3 years in Competitive Intelligence (within Marketing)
Kim has helped build the Competitive Intelligence function and foundation over the past 3 years at Ethicon. This has included developing internal systems to
help improve access and disseminate intelligence to the organization. Several of these systems have been highlighted as a Best Practice within J&J and are
being leveraged across the sectors. With the medical device business being quite different from the pharmaceutical industry, data access and availability is
extremely difficult to obtain. This has resulted in creative approaches to build competitive pipelines using a number of different sources available from public
domains. The past three years have been an incredibly exciting time in the medical device Competitive Intelligence business - it’s been a tremendous
learning curve for Kim.
Kim has a Bachelor’s of Science degree in Industrial Engineering and has been a member of SCIP for the past 2 years.
_____________________________________________________________________________________________________________________________
|
|
|
|
Arjan Singh
VP, Consulting
Fuld & Co.
Arjan Singh is VP, Consulting at Fuld & Company. He has worked with some of the largest companies across industries to create world-class intelligence
processes for numerous Fortune 500 companies in relatively short periods of time through the application of cutting edge CI methodology.
He created the Strategy and Competitive Intelligence course for the MBA program at UC Irvine's Paul Merage School of Business a few years ago and now
leads that class at the school.
He has trained over 1500 people in the concepts of CI at various venues including the Academy of Competitive Intelligence (ACI), Society of Competitive
Intelligence Professionals (SCIP) and in specific in house sessions for clients.
_____________________________________________________________________________________________________________________________
|
|
|
|
Richard Traxler
Senior Manager of Technology Planning
Boston Scientific Corporation
Richard’s resume includes Research & Development and Manufacturing Engineering management positions in Fortune 500 companies in the automotive,
(United Technologies Corporation), electronics, (Seagate Technology Corporation), and medical device industries (Boston Scientific Corporation). In his
current role as Senior Manager of Technology Planning at Boston Scientific's Cardiovascular Division, Richard has developed & implemented a highly
successful form of Technology Roadmapping that is a major element of Boston Scientific’s new product development portfolio planning. This roadmapping
practice has significantly helped focus Boston Scientific’s Research and Development investments. Richard has BS & MS degrees in Engineering and holds
seven medical device patents. He resides in Minneapolis with his wife and Labradoodle pup.
_____________________________________________________________________________________________________________________________
|
|
|
|
David Van Mook
Manager, CI
Roche Diagnostics
David Van Mook is currently Manager of Competitive Intelligence at Roche Diagnostics, with a specialization in global marketing issues. Prior to joining
Roche, Mr. Van Mook was a management consultant specializing in international competitive strategy for a broad range of multinationals. His education
includes an MBA from Kellogg Graduate School of Management at Northwestern University and graduation with high honors from Princeton University.
_____________________________________________________________________________________________________________________________
|
| |
|
Rakesh Verma
Director
CIS Lifesciences
Rakesh stated out is career as a vet in India. In order to further understand disease processes and immune responses he gained an MSc in Immunology with a
Distinction from the Royal Postgraduate Medical School, London and a Ph.D. in Immunology from Imperial College London in genetically engineering
recombinant therapeutic antibody fragments for clinical oncology applications.
At CIS Life Sciences Rakesh is a Director and responsible for maximizing the insight gleaned from pre-clinical and clinical programs with a particular focus on
Oncology, Immunology and biologics.
Prior to joining CIS Life Sciences, Rakesh had more than 12 years’ experience in the biopharmaceutical industry as a head of department at an oncology
focused company, Antisoma, where he initiated, developed and drove forward concepts and ideas to development stage projects. He is the inventor on
product-specific patent applications and has authored research articles, scientific reviews and book chapters. In addition, he has experience in writing
regulatory and CMC documentations, submitting patent applications, reviewing business development opportunities, due diligence and licensing. Rakesh has
made various presentations at international conferences, meetings and to collaborators and partners.
_____________________________________________________________________________________________________________________________
|
|
|
|
Raghu L. Vishwanath
CI Manager
Genzyme
Raghu Vishwanath is a Competitive Intelligence Manager at Genzyme Corporation's Competitive and Technical Information division. Raghu has been with
Genzyme for over 2 years and provides competitive intelligence to Genzyme's cardiovascular franchise. Raghu currently supports decision making by
providing both business and technical intelligence to the R&D, Business Development, and Commercial Development teams. In this capacity, Raghu
combines market analytics with scientific product attributes and unmet medical need analysis to identify niche market segments that enable product
positioning. In assessing Business Development initiatives vis-à-vis internal R&D programs, Raghu also provides strategic insight to the portfolio planning
process.
Raghu earned a Bachelor of Science degree in Chemistry and a Master of Science degree in Biochemistry from the University of Bombay. He followed this up
with graduate work at the University of Texas-Southwestern Medical Center, where his MS thesis focused on transcriptional control of exocrine pancreatic gene
expression. Raghu has nearly 10 years of experience in industry, most recently at Altana Pharma where he worked on Target Identification and Validation for
Oncology and Inflammation. During this period, Raghu received an MBA from Boston University's School of Management and subsequently moved on from
the laboratory with to work on cross-functional initiatives in the bio-pharmaceutical industry.
Raghu is a member of the Society of Competitive Intelligence Professionals (SCIP).
_____________________________________________________________________________________________________________________________
|
|
|
|
Sue Ward
Director, Competitive Intelligence
Pfizer, Worldwide Strategic Planning
Sue Ward is currently Director of Competitive Intelligence within Pfizer’s Corporate Strategic Planning group. Previously within Pfizer, Sue led the competitive
intelligence team within Information & Knowledge Management. Prior to joining Pfizer, Sue worked in the UK as Associate Director of Competitive Analysis
for SmithKline Beecham (SB) (now GSK). Other positions held by Sue within SB included managing a Clinical Information group and the Product Literature
Information Service. Sue holds a BSc (Hons) in Biology from University College London and an MSc in Information Science from The City University, London.
_____________________________________________________________________________________________________________________________
|
|
|
|
Friederike Wirtz-Brugger, Ph.D
Associate Director, Scientific Competitive Intelligence
Sanofi-Aventis
Twenty eight years experience in Pharmaceutical research both as a Research Scientist and Senior Manager of Scientific Competitive intelligence
Senior Manager, Scientific Competitive Intelligence (SCI) , Sanofi-Aventis, US and France (2003 - present)
- Providing and managing intelligence analyses of the competitive landscape for cardiovascular and
thrombosis indications as part of a global SCI group.
- Evaluation of competitor strategies, identification of trends and product licensing opportunities for
French managed company.
- Effective global communication of interpretation and recommendations based on competitive
analysis to the research community in US , France and Germany and global marketing and
development project teams.
Senior Research Scientist, Aventis Pharma, US and Germany (until 2003)
- Managing and leading several early drug discovery and research project teams in the area of multiples sclerosis and inflammatory neurological
disease processes.
- Extensive knowledge in disease areasof CV, Thrombosis and CNS.
- Played a leadership role in Aventis / Millennium Collaboration as a representative on both target
identification and validation teams.
Education:
Ph.D., Physiology and Neurobiology, UMDNJ (The University of Medicine and Dentistry of New Jersey) and Rutgers University, Graduate School, NJ, USA.
Diplom-Ingenieur, M.S. degree / Chemical and Biomedical Engineering, University Giessen, Germany.
____________________________________________________________________________________________________________________________
|
|
|
|
Richard Withers
CEO
Deallus
Richard is the CEO of the Dealllus Group. Following several years service as a military intelligence officer, Richard retired, went to Business School and
started consulting to the Pharmaceutical Industry on intelligence matters.
Over his career he has facilitated over 100 strategic workshops such as War Games and Scenario Analysis events and has advised CI Managers and their
Customers in R&D across to Marketing on what to expect from CI and how to derive maximum value from it.
_____________________________________________________________________________________________________________________________
|
|
|
|
Wendy Ye
Principal Competitive Intelligence
Medtronic Inc
Wendy Ye is a Principal Competitive Intelligence Specialist. She designed and implemented Competitive Intelligence program and process for Medtronic
Neuromodulation. She leads competitive analysis and created tools, web site to support strategic planning and business decision. Before joining Medtronic in
2004, Wendy worked for Lucent Technologies as Sr. CI specialist and project manager in telecommunication field.
Wendy also worked for GCC, a Boston based consulting firm on medical device and telecom related patent litigation support, where she provided Japanese
and US patent analysis and prior art search. Wendy started her career as a researcher and Biomedical Engineer at MIT, Division of Health Sciences and
Technology, and Harvard VA Medical Center.
Wendy received her BS from Zhejiang University, China and MS from Tokyo Institute of Technology, Japan.
_____________________________________________________________________________________________________________________________
|
| |
|
|
|
